Malta - Englisch - Malta Medicines Authority

baxter healthcare limited - phenylalanine; histidine; arginine; aspartic acid; olive oil; alanine; threonine; tyrosine; valine; glucose monohydrate; glutamic acid; glycine; methionine; isoleucine; l-tryptophan; lysine; serine; leucine; proline; soybean oil - emulsion for infusion - phenylalanine; histidine; arginine; aspartic acid; olive oil; alanine; threonine; tyrosine; valine; glucose monohydrate 250 g; glutamic acid; glycine; methionine; isoleucine; l-tryptophan; lysine; serine; leucine; proline; soybean oil - blood substitutes and perfusion solutions

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - aminolevulinic acid hydrochloride, quantity: 10.2 mg (equivalent: aminolevulinic acid, qty 8 mg) - patch, dermal - excipient ingredients: polyethylene terephthalate; polyethylene; aluminium; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - treatment of mild to moderate actinic keratoses (ak) lesions on the face and scalp (hairless areas).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; water for injections; sodium hydroxide; egg lecithin; glycerol; sodium oleate - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - chlorhexidine gluconate - mouthwash - 2mg/1ml

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - chlorhexidine gluconate - mouthwash - 2mg/1ml

Europäische Union - Englisch - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 125mg;  ; lumacaftor 100mg;   - film coated tablet - active: ivacaftor 125mg   lumacaftor 100mg   excipient: croscarmellose sodium hypromellose acetate succinate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry pink 85f140026 povidone sodium laurilsulfate water - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 2 years and older who are homozygous for the f508del mutation in the cftr gene.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 125mg;  ; lumacaftor 200mg;   - film coated tablet - active: ivacaftor 125mg   lumacaftor 200mg   excipient: croscarmellose sodium hypromellose acetate succinate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry pink 85f140026 povidone sodium laurilsulfate water - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 2 years and older who are homozygous for the f508del mutation in the cftr gene.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 125mg;  ; lumacaftor 100mg;   - oral granules - active: ivacaftor 125mg   lumacaftor 100mg   excipient: croscarmellose sodium hypromellose acetate succinate microcrystalline cellulose povidone sodium laurilsulfate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 2 years and older who are homozygous for the f508del mutation in the cftr gene.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 188mg;  ; lumacaftor 150mg;   - oral granules - active: ivacaftor 188mg   lumacaftor 150mg   excipient: croscarmellose sodium hypromellose acetate succinate microcrystalline cellulose povidone sodium laurilsulfate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 2 years and older who are homozygous for the f508del mutation in the cftr gene.